Search

Your search keyword '"Navarro-Compán, V."' showing total 423 results

Search Constraints

Start Over You searched for: Author "Navarro-Compán, V." Remove constraint Author: "Navarro-Compán, V."
423 results on '"Navarro-Compán, V."'

Search Results

2. OP0085 CLINICAL FEATURES OF PATIENTS WITH SpA, WITH OR WITHOUT IBD: RESULTS FROM THE METEOR COHORT

6. POS0194 FACTORS ASSOCIATED WITH RADIOGRAPHIC SPINAL PROGRESSION IN PATIENTS WITH AXIAL SPONDYLOARTHRITIS RECEIVING IL-17A INHIBITOR OR TNF INHIBITOR THERAPY: A POST-HOC ANALYSIS OF THE SURPASS STUDY

7. POS0215 LONG-TERM SAFETY AND EFFICACY OF BIMEKIZUMAB IN PATIENTS WITH ACTIVE ANKYLOSING SPONDYLITIS: 5-YEAR RESULTS FROM A PHASE 2B STUDY AND ITS OPEN-LABEL EXTENSION

13. Evaluación de la densidad mineral ósea y de los parámetros de 3D-Shaper en la hipofosfatasia congénita del adulto

14. Le bimékizumab permet le maintien des réponses cliniques évaluées par des critères stricts jusqu’à la semaine 52 chez les patients atteints de spondyloarthrite axiale : résultats des études de phase III BE MOBILE 1 et BE MOBILE 2

15. Tolérance et efficacité à long terme du bimékizumab chez les patients atteints de spondylarthrite ankylosante active : résultats à 5 ans d’une étude de phase IIb et de son extension en ouvert

16. Effet du sécukinumab versus adalimumab biosimilaire sur la progression radiographique chez les patients atteints de spondyloarthrite axiale radiographique : analyse en sous-groupes avec sur le statut syndesmophytes et protéine C-réactive à l’inclusion

17. Le bimékizumab réduit les lésions inflammatoires à l’IRM chez les patients atteints de spondyloarthrite axiale : résultats à la semaine 52 des études de phase III BE MOBILE 1 et 2

18. Moins de 10 % de probabilité de progression radiographique à 10 ans chez les patients avec spondyloarthrite axiale (axSpA) récente, et probablement moins de 5 % s’ils reçoivent un anti-TNF alpha : données de la cohorte DESIR

19. Effet du sécukinumab versus adalimumab biosimilaire sur la progression radiographique chez les patients atteints de spondyloarthrite axiale radiographique : étude randomisée de phase 3b

22. POS0246 BIMEKIZUMAB REDUCED MRI INFLAMMATORY LESIONS IN PATIENTS WITH AXIAL SPONDYLOARTHRITIS: WEEK 52 RESULTS FROM THE BE MOBILE 1 AND BE MOBILE 2 PHASE 3 STUDIES

24. AB0994 HOW SPONDYLOARTHRITIS PROFILE HAS EVOLVED OVERTIME: RESULTS FROM GESPA COLOMBIAN COHORT

26. AB1000 ACHIEVEMENT OF INCREASINGLY STRINGENT CLINICAL RESPONSE CRITERIA AND LOWER LEVELS OF DISEASE ACTIVITY WAS ASSOCIATED WITH GREATER IMPROVEMENTS IN PHYSICAL FUNCTION AND HRQOL IN PATIENTS WITH ACTIVE AXIAL SPONDYLOARTHRITIS: 52-WEEK RESULTS FROM TWO PHASE 3 STUDIES ON BIMEKIZUMAB

27. AB1010 WHICH FACTORS ARE ASSOCIATED WITH CLINICALLY HIGH DISEASE ACTIVITY IN AXIAL SPONDYLOARTHRITIS? RESULTS FROM THE INTERNATIONAL MAP OF AXIAL SPONDYLOARTHRITIS (IMAS)

29. AB1076 SPECTRUM OF AXIAL SPONDYLOARTHRITIS IN COLOMBIAN’S PATIENTS: NON-RADIOGRAPHIC VS RADIOGRAPHIC AXIAL SPA. RESULTS FROM GESPA COLOMBIAN COHORT

30. AB1023 THE DIFFERENTIAL CHARACTERISTIC OF SPONDYLOARTHRITIS PATIENTS WHO CANNOT BE CLASSIFIED ACCORDING TO ASAS: RESULTS FROM THE GESPA COLOMBIAN COHORT

31. OP0187 REGIONAL DIFFERENCES IN CLINICAL PHENOTYPE OF AXIAL SPONDYLOARTHRITIS. RESULTS FROM THE INTERNATIONAL MAP OF AXIAL SPONDYLOARTHRITIS (IMAS)

33. POS1104 BIMEKIZUMAB MAINTAINED STRINGENT CLINICAL RESPONSES THROUGH WEEK 52 IN PATIENTS WITH AXIAL SPONDYLOARTHRITIS: RESULTS FROM THE PHASE 3 STUDIES BE MOBILE 1 AND BE MOBILE 2

34. POS0683 AN EXPLORATORY ANALYSIS OF THE POTENTIAL DISCONNECT BETWEEN OBJECTIVE INFLAMMATORY RESPONSE AND CLINICAL RESPONSE FOLLOWING CERTOLIZUMAB PEGOL TREATMENT IN PATIENTS WITH ACTIVE AXIAL SPONDYLOARTHRITIS

36. POS0689 DIAGNOSTIC DELAY IN PATIENTS INCLUDED IN THE INTERNATIONAL MAP OF AXIAL SPONDYLOARTHRTIS: ASSOCIATIONS WITH GEOGRAPHIC, SOCIO-DEMOGRAPHIC AND DISEASE-RELATED FACTORS

37. POS1106 ACHIEVEMENT OF LOW DISEASE ACTIVITY OVER 52 WEEKS IN PATIENTS WITH ACTIVE AXIAL SPONDYLOARTHRITIS ON BIMEKIZUMAB TREATMENT: RESULTS FROM THE PHASE 3 STUDIES BE MOBILE 1 AND BE MOBILE 2

38. AB0987 FEMALES WITH AXIAL SPONDYLOARTHRITIS REPORT HIGHER BURDEN OF DISEASE AND WORSE PATIENT-REPORTED OUTCOMES. RESULTS FROM THE INTERNATIONAL MAP OF AXIAL SPONDYLOARTHRITIS (IMAS)

39. OP0059 EFFECT OF SECUKINUMAB VERSUS ADALIMUMAB BIOSIMILAR ON RADIOGRAPHIC PROGRESSION IN PATIENTS WITH RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS: A RANDOMISED PHASE IIIB STUDY

40. OP0008 EULAR RECOMMENDATIONS FOR THE USE OF IMAGING IN THE DIAGNOSIS AND MANAGEMENT OF CRYSTAL-INDUCED ARTHROPATHIES IN CLINICAL PRACTICE

41. POS0298 THE INTERNATIONAL MAP OF AXIAL SPONDYLOARTHRITIS (IMAS). RESULTS FROM THE PERSPECTIVE OF 5,557 PATIENTS FROM 27 COUNTRIES AROUND THE WORLD

42. OP0055 ASAS CONSENSUS DEFINITION OF EARLY AXIAL SPONDYLOARTHRITIS

44. OP0061 DEVELOPMENT OF EXTRA-MUSCULOSKELETAL MANIFESTATIONS IN UPADACITINIB-TREATED PATIENTS WITH PSORIATIC ARTHRITIS, ANKYLOSING SPONDYLITIS, OR NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS

45. AB1069 GENDER DIFFERENCES IN PRESENTATION, CLASSIFICATION, AND DISEASE ACTIVITY OF SPONDYLOARTHRITIS: RESULTS FROM GESPA COLOMBIAN COHORT

50. PCR196 Association of Clinical Response Criteria and Disease Activity Levels With Physical Function and HRQoL in Patients With Active Axial Spondyloarthritis: 16-Week Results From Two Phase 3 Randomised, Placebo-Controlled Studies

Catalog

Books, media, physical & digital resources